Nationwide Surveillance of Azole Resistance in Aspergillus Diseases
Open Access
- 1 August 2015
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (8), 4569-4576
- https://doi.org/10.1128/aac.00233-15
Abstract
Aspergillus disease affects a broad patient population, from patients with asthma to immunocompromised patients. Azole resistance has been increasingly reported in both clinical and environmental Aspergillus strains. The prevalence and clinical impact of azole resistance in different patient populations are currently unclear. This 1-year prospective multicenter cohort study aimed to provide detailed epidemiological data on Aspergillus resistance among patients with Aspergillus disease in Belgium. Isolates were prospectively collected in 18 hospitals (April 2011 to April 2012) for susceptibility testing. Clinical and treatment data were collected with a questionnaire. The outcome was evaluated to 1 year after a patient's inclusion. A total of 220 Aspergillus isolates from 182 patients were included. The underlying conditions included invasive aspergillosis (n = 122 patients), allergic bronchopulmonary aspergillosis (APBA) (n = 39 patients), chronic pulmonary aspergillosis (n = 10 patients), Aspergillus bronchitis (n = 7 patients), and aspergilloma (n = 5 patients). The overall azole resistance prevalence was 5.5% (95% confidence interval [CI] 2.8 to 10.2%) and was 7.0% (4/57; 95% CI, 2.3 to 17.2%) in patients with APBA, bronchitis, aspergilloma, or chronic aspergillosis and 4.6% in patients with invasive aspergillosis (5/108; 95% CI, 1.7 to 10.7%). The 6-week survival in invasive aspergillosis was 52.5%, while susceptibility testing revealed azole resistance in only 2/58 of the deceased patients. The clinical impact of Aspergillus fumigatus resistance was limited in our patient population with Aspergillus diseases.This publication has 32 references indexed in Scilit:
- Antifungal Susceptibilities of Aspergillus fumigatus Clinical Isolates Obtained in Nagasaki, JapanAntimicrobial Agents and Chemotherapy, 2012
- Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)Clinical Microbiology & Infection, 2011
- Clinical Implications of Azole Resistance inAspergillus fumigatus, the Netherlands, 2007–2009Emerging Infectious Diseases, 2011
- Outcome Analysis of Invasive Aspergillosis in Hematologic Malignancy and Hematopoietic Stem Cell Transplant Patients: The Role of Novel Antimold AzolesThe Oncologist, 2011
- Aspergillus Species and Other Molds in Respiratory Samples from Patients with Cystic Fibrosis: a Laboratory-Based Study with Focus on Aspergillus fumigatus Azole ResistanceJournal of Clinical Microbiology, 2011
- Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignanciesJournal of Antimicrobial Chemotherapy, 2010
- Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)Journal of Clinical Microbiology, 2010
- Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009Journal of Antimicrobial Chemotherapy, 2010
- Azole Resistance Profile of Amino Acid Changes in Aspergillus fumigatus CYP51A Based on Protein Homology ModelingAntimicrobial Agents and Chemotherapy, 2010
- Multiple-azole-resistantAspergillus fumigatusosteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgeryMedical Mycology, 2009